14 |
Klinisk Biokemi i Norden · 3 2013
hvor interventionsarmen udsættes for kombinationen
af diagnostik og den behandling, der forventes at virke,
når biomarkøren viser en abnorm værdi. Speciallæger
i klinisk biokemi og andre akademiske medarbejdere
bør i samarbejde med klinikere kræve den rette kli-
niske evidens før indførelse af en ny biomarkør for at
undgå alvorlig skade hos patienter.
Referencer
1. Statistical Guidance on Reporting Results from
Studies Evaluating Diagnostic Test. FDA 2007.
2. Kollef MH, Sherman G, Ward S, Fraser VJ. Ina-
dequate antimicrobial treatment of infections:
a risk factor for hospital mortality among cri-
tically ill patients. Chest 1999;115:462–74.
3. Kumar A, Roberts D, Wood KE, Light B, Par-
rillo JE, Sharma S, et al. Duration of hypoten-
sion before initiation of effective antimicrobial
therapy is the critical determinant of survi-
val in human septic shock. Crit Care Med
2006;34:1589–96.
4. Russwurm S, Wiederhold M, Oberhoffer M,
Stonans I, Zipfel PF, Reinhart K. Molecular
aspects and natural source of procalcitonin.
Clin Chem Lab Med 1999;37:789–97.
5. Nobre V, Harbarth S, Graf J-D, Rohner P,
Pugin J. Use of procalcitonin to shorten anti-
biotic treatment duration in septic patients: a
randomized trial. Am J Respir Crit Care Med
2008;177:498–505.
6. Schuetz P, Müller B, Stolz D, Tamm M, Bou-
adma L, Ce L, et al. Procalcitonin to initiate
or discontinue antibiotics in acute respiratory
tract infections. Cochrane Database Syst Rev.
2012;(9).
7. Jensen JU, Heslet L, Jensen TH, Espersen K,
Steffensen P, Tvede M. Procalcitonin increase
in early identification of critically ill patients
at high risk of mortality. Crit Care Med
2006;34:2596–602.
8. Müller B, Becker KL, Schächinger H, Ricken-
bacher PR, Huber PR, Zimmerli W, et al. Cal-
citonin precursors are reliable markers of sepsis
in a medical intensive care unit. Crit Care Med
2000;28:977–83.
9. Gaïni S, Koldkjaer OG, Møller HJ, Pedersen C,
Pedersen SS. A comparison of high-mobility
group-box 1 protein, lipopolysaccharide-bin-
ding protein and procalcitonin in severe com-
munity-acquired infections and bacteraemia: a
prospective study. Crit care 2007;11:R76.
10. Jensen JU, Lundgren B, Hein L, Mohr T,
Petersen PL, Andersen LH, et al. The Procal-
citonin And Survival Study (PASS) - a rando-
mised multi-center investigator-initiated trial
to investigate whether daily measurements
biomarker Procalcitonin and pro-active diag-
nostic and therapeutic responses to abnormal
Procalcitonin levels, can improve survival in
intensive care unit patients. Calculated sample
size (target population): 1000 patients. BMC
Infect Dis 2008;8:91.
11. Jensen JU, Hein L, Lundgren B, Bestle MH,
Mohr TT, Andersen MH, et al. Procalcito-
nin-guided interventions against infections
to increase early appropriate antibiotics and
improve survival in the intensive care unit: a
randomized trial. Crit Care Med 2011;39:2048–
58.
12. Jensen J-US, Hein L, Lundgren B, Bestle MH,
Mohr T, Andersen MH, et al. Kidney failure
related to broad-spectrum antibiotics in criti-
cally ill patients: secondary end point results
from a 1200 patient randomised trial. BMJ
Open 2012 Jan;2:e000635.
13. Hochreiter M, Köhler T, Schweiger AM, Keck
FS, Bein B, Von Spiegel T, et al. Procalcitonin
to guide duration of antibiotic therapy in inten-
sive care patients: a randomized prospective
controlled trial. Crit care 2009;13:R83.
14. Stolz D, Smyrnios N, Eggimann P, Pargger H,
Thakkar N, Siegemund M, et al. Procalcitonin
for reduced antibiotic exposure in ventilator-
associated pneumonia: a randomised study. Eur
Respir J 2009;34:1364–75.
15. Bouadma L, Luyt C-E, Tubach F, Cracco C,
Alvarez A, Schwebel C, et al. Use of procalci-
tonin to reduce patients’ exposure to antibio-
tics in intensive care units (PRORATA trial): a
multicentre randomised controlled trial. Lancet
2010;375:463–74.
